Biocon Biologics settles patent issue; paves way for launch of biosimilar product in Canada
Biocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalmology product for neovascular and age-related macular degeneration, in Canada by July 1, 2025.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Age-Related Macular Degeneration (AMD) | Biotechnology | Canada Health | Opthalmology | Pharmaceuticals